Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.
作者信息
McCord Matthew, Jamshidi Pouya
机构信息
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
出版信息
Neuro Oncol. 2024 Jun 3;26(6):1097-1098. doi: 10.1093/neuonc/noae062.
Abstract
摘要
相似文献
1
Targeting the cell cycle to enhance chemotherapy efficacy in glioblastoma.靶向细胞周期以提高胶质母细胞瘤的化疗疗效。
Neuro Oncol. 2024 Jun 3;26(6):1097-1098. doi: 10.1093/neuonc/noae062.
2
Emerging therapeutic targets and agents for glioblastoma therapy - part I.胶质母细胞瘤治疗的新兴治疗靶点与药物——第一部分。
Anticancer Agents Med Chem. 2010 Jul;10(6):437. doi: 10.2174/1871520611009060437.
3
Emerging therapeutic targets and agents for glioblastoma therapy--part II.胶质母细胞瘤治疗的新兴治疗靶点与药物——第二部分
Anticancer Agents Med Chem. 2010 Sep;10(7):511. doi: 10.2174/187152010793498672.
4
Targeting Glioblastoma: Efficacy of Ruthenium-Based Drugs.靶向脑胶质瘤：钌类药物的疗效。
Chem Res Toxicol. 2024 Sep 16;37(9):1453-1455. doi: 10.1021/acs.chemrestox.4c00188. Epub 2024 Aug 20.
5
Proneural-mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?胶质瘤干细胞的神经前体细胞-间充质转化：治疗是否会导致胶质母细胞瘤中靶点的演变？
Future Oncol. 2014;10(9):1527-30. doi: 10.2217/fon.14.86.
6
Encapsulated Butylidenephthalide Efficiently Crosses the Blood-Brain Barrier and Suppresses Growth of Glioblastoma.包裹丁烯基邻苯二甲酸二丙烯酯有效穿过血脑屏障并抑制神经胶质瘤生长。
Int J Nanomedicine. 2020 Jan 31;15:749-760. doi: 10.2147/IJN.S235815. eCollection 2020.
7
SnapShot: glioblastoma multiforme.简讯：多形性胶质母细胞瘤
Cancer Cell. 2012 May 15;21(5):710-710.e1. doi: 10.1016/j.ccr.2012.04.031.
8
STAT3 as a Therapeutic Target for Glioblastoma.STAT3 作为胶质母细胞瘤的治疗靶点。
Anticancer Agents Med Chem. 2010 Sep;10(7):512-9. doi: 10.2174/187152010793498636.
9
Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.洛莫司汀与二十二碳六烯酸联合使用对胶质母细胞瘤细胞系的抗癌特性增强
J Neurosurg. 2015 Mar;122(3):547-56. doi: 10.3171/2014.10.JNS14759. Epub 2014 Dec 19.
10
Chemotherapy for high-grade gliomas.高级别胶质瘤的化疗
Br J Cancer. 2000 Apr;82(8):1371-80. doi: 10.1054/bjoc.1999.1075.
引用本文的文献
1
Innovative dual-gene delivery platform using miR-124 and PD-1 via umbilical cord mesenchymal stem cells and exosome for glioblastoma therapy.通过脐带间充质干细胞和外泌体使用miR-124和PD-1的创新双基因递送平台用于胶质母细胞瘤治疗。
J Exp Clin Cancer Res. 2025 Mar 25;44(1):107. doi: 10.1186/s13046-025-03336-4.
本文引用的文献
1
Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.取消 G2/M 检查点作为烷化剂的化疗增敏方法。
Neuro Oncol. 2024 Jun 3;26(6):1083-1096. doi: 10.1093/neuonc/noad252.
2
Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.利用患者来源的异种移植物模拟胶质母细胞瘤的治疗驱动进化
Cancers (Basel). 2022 Nov 9;14(22):5494. doi: 10.3390/cancers14225494.
3
Glioma progression is shaped by genetic evolution and microenvironment interactions.胶质瘤的进展是由遗传进化和微环境相互作用决定的。
Cell. 2022 Jun 9;185(12):2184-2199.e16. doi: 10.1016/j.cell.2022.04.038. Epub 2022 May 31.
4
Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma.全基因组 CRISPR/Cas9 筛选鉴定出 CARHSP1 是胶质母细胞瘤辐射抵抗的关键。
Cell Death Dis. 2021 Jul 21;12(8):724. doi: 10.1038/s41419-021-04000-3.
5
Mechanisms and therapeutic implications of hypermutation in gliomas.胶质母细胞瘤中突变的机制及治疗意义。
Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15.
6
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
7
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.全基因组 CRISPR-Cas9 筛选揭示胶质母细胞瘤干细胞对替莫唑胺敏感性的遗传脆弱性和机制。
Cell Rep. 2019 Apr 16;27(3):971-986.e9. doi: 10.1016/j.celrep.2019.03.047.
8
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.新型改良的 IDH 突变型星形细胞瘤分级系统。
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.
9
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.MSH6突变在替莫唑胺治疗期间出现在胶质母细胞瘤中，并介导替莫唑胺耐药。
Clin Cancer Res. 2009 Jul 15;15(14):4622-9. doi: 10.1158/1078-0432.CCR-08-3012. Epub 2009 Jul 7.
10
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.放疗联合同步及辅助替莫唑胺治疗胶质母细胞瘤
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
Zotero 插件